Key Details
Price
$1.45Annual ROE
31.93%Beta
3.91Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
N/ARecent annual earnings:
N/ANext ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Nov 29, 2024Analyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,221,523 of the Company's ordinary shares originally issued in January 2025 having an exercise price of $1.35 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-282932). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $3.3 million, prior to deducting placement agent fees and estimated offering expenses. The offering is expected to close on or about January 30, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering as working capital for general corporate purposes.
Silexion Therapeutics Corp. SLXN revealed new preclinical results demonstrating the synergistic efficacy of its SIL-204, in combination with components of first-line chemotherapy for pancreatic cancer.
Cayman Islands, January 15, 2025 -- Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the pricing of a public offering of an aggregate of 3,703,703 of the Company's ordinary shares (or ordinary share equivalents) and warrants to purchase up to 3,703,703 ordinary shares at a combined public offering price of $1.35 per share (or per ordinary share equivalent) and accompanying warrant. The warrants will have an exercise price of $1.35 per share, will be exercisable immediately upon issuance and will expire five years from the date of issuance. The closing of the offering is expected to occur on or about January 17, 2025, subject to the satisfaction of customary closing conditions.
Trading on split-adjusted basis will begin at market open on November 29, 2024. This adjustment is expected to help Silexion comply with NASDAQ requirements, enhance its market position, and support its strategic growth initiatives Trading on split-adjusted basis will begin at market open on November 29, 2024. This adjustment is expected to help Silexion comply with NASDAQ requirements, enhance its market position, and support its strategic growth initiatives
FAQ
- What is the ticker symbol for Biomotion Sciences?
- Does Biomotion Sciences pay dividends?
- What sector is Biomotion Sciences in?
- What industry is Biomotion Sciences in?
- What country is Biomotion Sciences based in?
- When did Biomotion Sciences go public?
- Is Biomotion Sciences in the S&P 500?
- Is Biomotion Sciences in the NASDAQ 100?
- Is Biomotion Sciences in the Dow Jones?
- When does Biomotion Sciences report earnings?
- Should I buy Biomotion Sciences stock now?